Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Flex LNG - Ex Date Q2 2025

(NYSE:FLNG) HAMILTON, Bermuda, Sept. 4, 2025 /PRNewswire/ -- The shares in Flex LNG Ltd. (Ticker: FLNG) traded on Oslo Stock Exchange ("OSE") and registered with Euronext Securities Oslo will trade...

How does this dividend yield compare with other LNG sector peers and could it influence investor allocation? Is the $0.75 USD per share dividend sustainable given the company’s cash flow and upcoming capital expenditures? How will the ex‑dividend date affect Flex LNG’s intraday price movement?
Symbol: FLNG
Dividends
9 days ago
Read more prnewswire

Skanska builds data center in Finland for EUR 95M, about SEK 1.1 billion

(SK) STOCKHOLM, Sept. 4, 2025 /PRNewswire/ -- Skanska has signed a contract with a technology company to build a data center facility in Finland. The contract is worth EUR 95M, about SEK 1.1 billio...

How does this deal position Skanska relative to its peers in the infrastructure/build‑to‑rent segment, and could it influence market perception of the company's growth outlook? What is the margin profile and risk exposure (e.g., client credit, currency, construction timeline) of this new data‑center project compared with similar contracts in the Nordic region? How will the EUR 95 million Finnish data‑center contract affect Skanska's Q3 earnings and order‑book guidance?
Symbol: SK
Contracts
9 days ago
Read more prnewswire

Sampo plc’s share buybacks 3 September 2025

(SAMPO) Sampo plc, stock exchange release, 4 September 2025 at 8:30 am EEST

Does the buyback indicate a shift in SAMPO's capital‑return strategy that could affect future dividend policy or reinvestment plans? What is the size of the buyback relative to SAMPO's cash reserves and how does it compare to the buyback programs of peer companies in the sector? How will the announced share buyback influence SAMPO's short‑term price dynamics and trading volumes?
Symbol: SAMPO
Buybacks
9 days ago
Read more globenewswire

Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

(NASDAQ:SNY) Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

When can we expect FDA submission and potential approval timelines for amlitelimab, and how might that impact long‑term market potential and revenue forecasts? What are the implications of amlitelimab’s success for Sanofi’s competitive positioning against other atopic dermatitis therapies such as Dupixent and other emerging biologics? How will the positive COAST 1 results affect Sanofi’s upcoming earnings guidance and stock valuation?
Symbol: SNY
Clinical trials
9 days ago
Read more globenewswire